Cyclacel Pharmaceuticals ( (CYCC) ) just unveiled an update.
On March 31, 2025, Cyclacel Pharmaceuticals announced the delayed resignation of its co-principal financial officer, David Lazar, and two independent directors, Avraham Ben-Tzvi and David Natan, until the filing of the company’s annual report. Subsequently, on April 2, 2025, the company appointed two new independent directors, Ms. Inigo Angel Laurduraj and Dr. Satis Waran Nair Krishnan, to its board. The company also reported financial results for the fourth quarter, highlighting a strategic focus on developing plogosertib, a PLK1 inhibitor for advanced cancers, and the liquidation of its subsidiary, Cyclacel Limited, which is expected to reduce research and development expenses and increase stockholders’ equity by approximately $5 million.
More about Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative cancer medicines based on cell cycle, epigenetics, and mitosis biology. The company is particularly focused on its epigenetic/anti-mitotic program, evaluating plogosertib, a PLK1 inhibitor, for treating both solid tumors and hematological malignancies.
YTD Price Performance: -27.30%
Average Trading Volume: 2,346,515
Technical Sentiment Signal: Strong Buy
Current Market Cap: $57.89M
Learn more about CYCC stock on TipRanks’ Stock Analysis page.